RT Journal Article
SR Electronic
T1 Impact of blood analysis and immune function on the prognosis of patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20067587
DO 10.1101/2020.04.16.20067587
A1 Yue-qiang Fu
A1 Yue-lin Sun
A1 Si-wei Lu
A1 Yang Yang
A1 Yi Wang
A1 Feng Xu
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.16.20067587.abstract
AB Introduction This retrospective study investigated the implications of changes in blood parameters and cellular immune function in patients with 2019-coronavirus infected disease (COVID-19).Methods Records were reviewed of 85 patients with COVID-19 between February 4 and 16, 2020. The primary outcome was in-hospital mortality at 28 days.Results Fourteen patients died. The baseline leukocyte count, neutrophil count and hemoglobin was significantly higher in non-survivors compared with survivors, while the reverse was true of lymphocyte count, platelet, PaO2/FiO2, CD3+ count and CD4+ count. The percentage of neutrophil count > 6.3×109/L in death group was significantly higher than that in survival group, and multivariate logistic regression showed neutrophil count was independently associated with mortality. However, there were not significant difference in IgG, IgM, IgA, C3, C4 and the percentage of IgE > 100 IU/ml between the death group and survival group. Areas under the receiver operating characteristic curves of the following at baseline could significantly predict mortality: leukocyte, neutrophil, lymphocyte, CD3+ and CD4+ counts.Conclusions For patients with COVID-19, lymphocyte, CD3+ and CD4+ counts that marked decrease suggest a poor outcome. A high neutrophil count is independently associated with mortality. At admission, leukocyte, neutrophil, lymphocyte, CD3+ and CD4+ counts should receive added attention.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective observational study without a trial registration number.Funding StatementThis project was supported by the Medjaden Academy & Research Foundation for Young Scientists (Grant No. COVID-19-MJA20200323)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.